Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 4, 2014, Pages 513-519

  Cercek, Andrea ^a   Goodman, Karyn A ^a   Hajj, Carla ^a   Weisberger, Emily ^a   Segal, Neil H ^a   Reidy Lagunes, Diane L ^a   Stadler, Zsofia K ^a   Wu, Abraham J ^a   Weiser, Martin R ^a   Paty, Philip B ^a   Guillem, Jose G ^a   Nash, Garrett M ^a   Temple, Larissa K ^a   Garcia Aguilar, Julio ^a   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL MUCOSITIS; PATIENT MONITORING; PRIMARY TUMOR; RECTUM CANCER; RECTUM SURGERY; THROMBOCYTOPENIA; TOTAL MESORECTAL EXCISION; TREATMENT PLANNING; TUMOR REGRESSION; TUMOR VOLUME; VOMITING; ABDOMINAL SURGERY; ADENOCARCINOMA; ADJUVANT THERAPY; MIDDLE AGED; PATHOLOGY; PROCEDURES; RECTAL NEOPLASMS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84900441043     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0056     Document Type: Article

References (31)

1. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
2. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
3. Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst 1988;80:21-29. (Pubitemid 18076565)
4. Prolongation of the disease-free interval in surgically treated rectal carcinoma. Gastrointestinal Tumor Study Group. N Engl J Med 1985;312:1465-1472.
5. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30. (Pubitemid 41095110)
6. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-1214. (Pubitemid 41079833)
7. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351. (Pubitemid 38702845)
8. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947. (Pubitemid 30644117)
9. Cercek A, Weiser M, Goodman KA, et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 3649
10. Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant FOLFOX-bev without radiation, for locally advanced rectal cancer [abstract]. J Clin Oncol 2010;28(Suppl 1):Abstract 3511.
11. Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol 2006;24:668-674. (Pubitemid 46630432)
12. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol 2010;28:859-865.
13. Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-1471.
14. Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-3774.
15. Washington MK, Berlin J, Branton LJ, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 2009;133:1539-1551.
16. Sinicrope F, Mahoney MR, Smyrk TC, et al. Prognositic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013;31:3664-3672.
17. Hugen N, Verhoevem RH, Lemmens VE, et al. Colorectal signet-ring cell carcinoma: responsive to adjuvant chemotherapy but still a poor prognosis [abstract]. J Clin Oncol 2014;32(Suppl 3):Abstract 529.
18. Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 2010;11:241-248.
19. Gerard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006;24:4620-4635.
20. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-1123. (Pubitemid 44394918)
21. Land SR, Ritter MW, Costantino JP, et al. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. J Clin Oncol 2007;25:5113-5120. (Pubitemid 350232292)
22. Goldberg PA, Nicholls RJ, Porter NH, et al. Long-term results of a randomised trial of short-course low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment failure. Eur J Cancer 1994;30A:1602-1606. (Pubitemid 24355472)
23. van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011;12:575-582.
24. Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol 2009;92:210-214.
25. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010;11:835-844.
26. Capirci C, Valentini V, Cionini L, et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008;72:99-107.
27. Chang GJ, Rodriguez-Bigas MA, Eng C, et al. Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. Cancer 2009;115:5432-5440.
28. Das P, Skibber JM, Rodriguez-Bigas MA, et al. Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 2006;29:219-224. (Pubitemid 44270928)
29. Kuo LJ, Liu MC, Jian JJ, et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? Ann Surg Oncol 2007;14:2766-2772. (Pubitemid 47460637)
30. Quah HM, Chou JF, Gonen M, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008;113:57-64. (Pubitemid 351976386)
31. Stipa F, Chessin DB, Shia J, et al. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography. Ann Surg Oncol 2006;13:1047-1053. (Pubitemid 44337963)